SCHEMBL22246010

SCHEMBL22246010

O=C1OCC(c2ccc(Cl)s2)=C1c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.59
PTGS1 P23219 5/20 0.50
PTGS2 P35354 7/20 0.46
ALDH1A1 P00352 3/20 0.46
ABCB11 O95342 1/20 0.46
MT-CO2 P00403 1/20 0.46
HTR1A P08908 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
MC4R P32245 1/20 0.46
POLB P06746 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP2A6 P11509 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22246041 0.89 KMT2A (0.45) KMT2APTGS1PTGS2ALDH1A1ABCB11
SCHEMBL22246038 0.87 PTGS2 (0.50) KMT2APTGS1PTGS2HSD17B1HSD17B2
SCHEMBL22246020 0.87 PTGS1 (0.57) KMT2APTGS1PTGS2
SCHEMBL26200536 0.87 PTGS1 (0.55) KMT2APTGS1PTGS2ALDH1A1ABCB11
SCHEMBL22246144 0.87 PRF1 (0.45) KMT2APTGS1PTGS2HSD17B10CYP2A6
SCHEMBL22246013 0.85 KMT2A (0.41) KMT2APTGS1PTGS2HSD17B1HSD17B2
SCHEMBL26200500 0.85 KMT2A (0.40) KMT2APTGS1PTGS2ALDH1A1ABCB11
SCHEMBL22246012 0.84 KMT2A (0.39) KMT2APTGS1PTGS2ALDH1A1POLB
SCHEMBL22246039 0.83 PTGS1 (0.58) KMT2APTGS1PTGS2ALDH1A1CYP1A2
SCHEMBL22246138 0.83 CYP2A6 (0.61) KMT2ACYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744826-B2 Compounds and methods of treating retinal degeneration CASE WESTERN RESERVE UNIVERSITY (US) 2023-09-05 US disclosed
US-20220087992-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
US-11191752-B2 Compounds and methods of treating retinal degeneration CASE WESTERN RESERVE UNIVERSITY (US) 2021-12-07 US disclosed
US-20200230119-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION CASE WESTERN RESERVE UNIVERSITY 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087992-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION ALDH1A2, PDE6D, PDE6C KMT2A 4688/4885PTGS1 348/4885PTGS2 475/4885
US-20200230119-A1 COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION PDE6A, PDE6H, PDE6D KMT2A 4586/4885PTGS1 394/4885PTGS2 766/4885
US-11744826-B2 Compounds and methods of treating retinal degeneration ALDH1A2, PDE6D, PDE6C KMT2A 4688/4885PTGS1 348/4885PTGS2 475/4885
US-11191752-B2 Compounds and methods of treating retinal degeneration PDE6A, PDE6H, PDE6D KMT2A 4586/4885PTGS1 394/4885PTGS2 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.